MAAT
Maat Pharma
Amount
~€9K
@ €3.48 / per share
Detailed Analysis
Senda Bouchrara (A regulated executive) purchased ~€9K in Maat Pharma (MAAT) on XPAR on 18 Nov 2025, with a 9-day disclosure delay. An open-market purchase with no compensation or vesting context — real personal capital committed at market prices. The discretionary nature is the primary signal here.
Price history — MAAT
Price since trade
+72.38%
SPY since trade
+11.98%
Trade date
18 November 2025
When the trade occurred
Disclosed date
26 November 2025
8-day delay
Disclosure delay: 8 days. This trade was reported to regulators 8 days after it occurred. By the time this filing became public, markets had 8 additional days to react to any non-public information.
Reference data
Use these identifiers to look up this instrument in your own platform. Disclosyr does not link to any broker.
Ticker
MAAT
ISIN
FR0012634822
Exchange
XPAR
Company
Maat Pharma
Filed with amf france on 26 November 2025